Table 2.
Univariate and multivariate analyses of factors associated with overall survival and time to treatment failure.
| Characteristic* | 2-year OS | Univariate HR | 95% CI | Univariate p value | Multivariate HR | 95% CI | Multivariate p value | |
| NLR | < 5 | 60% | Ref | <0.001 | Ref | -- | ||
| ≥ 5 | 33% | 2.05 | 1.42–2.97 | 1.95 | 1.33–2.86 | 0.001 | ||
| Primary site | Cutaneous | 52% | Ref | 0.002 | Ref | -- | ||
| Mucosal | 28% | 2.05 | 1.27–3.31 | 2.08 | 1.28–3.37 | 0.003 | ||
| Unknown primary | 71% | 0.68 | 0.40–1.19 | 0.58 | 0.33–1.01 | 0.054 | ||
| Number of metastatic sites | 1 | 71% | Ref | <0.001 | Ref | -- | ||
| 2–3 | 51% | 2.12 | 1.24–3.61 | 1.85 | 1.08–3.17 | 0.026 | ||
| ≥ 4 | 38% | 3.04 | 1.72–5.38 | 2.61 | 1.15–4.67 | 0.001 | ||
| ECOG status | 0 | 62% | Ref | 0.003 | -- | -- | ||
| 1 | 44% | 1.52 | 1.04–2.23 | -- | -- | |||
| 2+ | 32% | 2.55 | 1.41–4.62 | -- | -- | |||
| AJCC M stage | M1a | 64% | Ref | 0.003 | -- | -- | ||
| M1b | 76% | 0.74 | 0.33–1.65 | -- | -- | |||
| M1c | 46% | 1.63 | 0.85–3.09 | -- | -- | |||
| M1d | 43% | 2.09 | 1.07–4.08 | -- | -- | |||
| Characteristic* | 2-year TTF | Univariate HR | 95% CI | Univariate p value | Multivariate HR | 95% CI | Multivariate p value | |
| NLR | < 5 | 32% | Ref | 0.003 | Ref | -- | ||
| ≥ 5 | 21% | 1.65 | 1.19–2.29 | 1.73 | 1.24–2.41 | 0.001 | ||
| Primary site | Cutaneous | 31% | Ref | 0.005 | Ref | -- | ||
| Mucosal | 7% | 1.86 | 1.20–2.87 | 1.80 | 1.16–2.78 | 0.008 | ||
| Unknown primary | 38% | 0.78 | 0.5–1.21 | 0.69 | 0.44–1.08 | 0.109 | ||
| ECOG status | 0 | 30% | Ref | 0.035 | -- | -- | ||
| 1 | 30% | 1.23 | 0.88–1.70 | -- | -- | |||
| 2+ | 21% | 1.99 | 1.16–3.41 | -- | -- |
*
Variables not listed were not significantly associated with the given outcome in univariate analysis. For both models, ECOG status was not significant after multivariate adjustment and thus was excluded from the final models. AJCC M stage was not included in multivariate analysis, as it was co-linear with number of metastatic sites.